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ABSTRACT 
 
Up to 20% of pregnant women smoke and there is indirect evidence that certain 
tobacco-specific metabolites can cross the placental barrier and are genotoxic to the 
fetus. The presence of micronuclei results from chromosome damage and reflects the 
degree of underlying genetic instability. Fetal blood was obtained from the cord blood 
of 143 newborns (102 from nonsmoking mothers and 41 from mothers smoking >10 
cigarettes/d during pregnancy). The micronucleus assay was performed following the 
guidelines established by the Human MicroNucleus project with modifications. To test 
the micronucleus assay, we evaluated the effect of a range of benzopyrene-7,8-diol-
9,10-epoxide concentrations (from 3.125 nM to 4 µM on cord blood from nonsmoking 
mothers. This validation showed that the number of micronuclei and apoptotic cells 
increased with benzopyrene-7,8-diol-9,10-epoxide dose (p < 0.0001 and p = 0.001, 
respectively); the minimal detectable effect was induced by 12.5 nM benzopyrene-7,8-
diol-9,10-epoxide. In our sample, the number of MN was significantly higher in the 41 
cord blood samples from mothers who smoked during pregnancy [smokers: 4 (1; 10.5); 
non-smokers: 3 (0; 8); p = 0.016]. Therefore, the data reported herein support the 
hypothesis that tobacco compounds are able to induce chromosomal losses and breaks 
that are detectable as an increased number of micronuclei.  
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INTRODUCTION 
 
Tobacco carcinogenicity is dependent on the activation of solid phase neutral 
compounds in the smoke by organic enzymes (CYP1A1, GST). Once activated, these 
compounds are able to induce molecular alterations (mutation in target genes) and 
cellular alterations (chromosomal aberrations and micronuclei induction). The activated 
molecule capable of causing most genetic damage is BPDE, which is able to establish 
covalent bonds with DNA and derives from benzopyrene (BP, neutral-solid phase) after 
a series of biotransformations mediated by the P450 enzymatic system (1,2). 
 
Tobacco consumption among women is an important problem, given the increasing rate 
and effects on fertility and gestation (3); it is estimated that 12–20% of women smoke 
during pregnancy (4), although the exact rate is difficult to establish because many 
pregnant women deny being smokers in their first clinical consultation. Certain tobacco 
compounds can cross the placental barrier and induce alterations in fetal development 
and growth (5). The presence of tobacco-specific metabolites has been detected in the 
fetal fluids and urine of fetuses and newborns, which strongly suggests a genotoxic 
effect of tobacco smoke upon newborns from mothers who smoke during pregnancy 
(6,7). Although different studies have demonstrated the presence of chromosomal 
aberrations, sister chromatid exchanges and/or increased number of micronuclei in 
peripheral blood from smokers, which reflect different types of genetic instability, the 
effect of the genotoxic agents on the fetus is poorly documented. Recently, de la Chica 
and coworkers (8) have demonstrated that smoking 10 cigarettes or more during 
pregnancy significantly increases chromosomal instability in amniocytes represented by 
an increased number of gaps, breaks, and structural chromosomal aberrations. What is 
more, they detected that the chromosomal region most affected by tobacco smoke was 
11q23, a region frequently altered in different neoplasias of hematologic origin. 
 
MN are cytoplasmic bodies of nuclear origin corresponding to genetic material such as 
whole chromosomes or chromosome fragments, which, during cell division, have not 
been incorporated in the main nuclei of daughter cells. The unincorporated 
chromosomal material is the result of chromosome breaks and/or errors during the 
replication and division of DNA and reflect the underlying genetic instability (9). The 
use of MN as a method to estimate genetic instability was improved with the 
development of the cytokinesis-block micronucleus (CBMN) assay, which allows MN 
to be scored specifically in cells that have completed only one nuclear division. The 
CBMN assay has since been validated by an international and multicentric committee 
(HUMN) (10) and is one of the most commonly used methods for evaluating the effects 
of potential mutagens on human lymphocytes. 
 
Some of the studies on MN frequency in human populations found that cigarette smoke 
did not affect MN frequency (11–13), whereas many others (14–16) found that smoking 
and increased MN index were positively correlated. These different results may be due 
to differences in definitions of the eligibility criteria of the smoking group. Two recent 
publications (17,18) detected a significant increase in MN frequency in individuals 
smoking more than 20 cigarettes per day. 
 
The aims of the study reported here were to establish and validate a MN assay protocol 
applicable to cord blood samples and then to use this assay to assess the genotoxic 
effect of tobacco derivatives on the fetal blood of newborns whose mothers smoked 
during pregnancy. 
 
 
 
METHODS 
 
Patients and samples 
 
Fetal blood samples with CPDA-1 as anticoagulant (CPDA, citrate, sodium phosphate, 
dextrose and adenine; Terumo Medical Corporation, Somerset, NJ) were obtained from 
the cord blood of 143 newborns (102 from mothers who never smoked and 41 from 
mothers who were smoking more than 10 cigarettes per day during pregnancy). The 
study was approved by the Human Ethics Committee of the University Clinic and 
Virgen del Camino Hospital in Pamplona, Spain. All participants were informed about 
the protocol and written informed consent was obtained. 
 
Only samples from pregnancies without complications and that concluded in 
spontaneous births at term (37–42 wk) were included. The samples came from a 
randomly chosen consecutive series of women who fulfilled the inclusion criteria 
described above and who were matched for age. In all cases, both the mother and father 
completed a questionnaire covering their medical history, exposure to chemicals, and 
passive and active tobacco smoke exposure at home and at work. For a subset of 
randomly selected cases and for all in which mother and father gave contradictory 
answers in their questionnaires (n = 10), the cotinine levels, the main metabolite of 
nicotine, were determined in maternal urine by gas chromatography-mass spectrometry, 
which has a sensitivity of 20 ng/mL (Reference Laboratory, Barcelona, Spain) (19). 
 
 
MN assay 
 
Fresh blood was diluted 1:1 with Hank’s solution (Invitrogen, Carlsbad, CA) and 
lymphocytes were isolated by red blood cells sedimentation by Lymphoprep gradient 
(Nycomed, Roskilde, Denmark). Cell concentration was measured using a 
hemocytometer and 500,000 viable cells (determined by trypan blue staining) were 
cultured in RPMI 1640 medium (Invitrogen) containing 10% FCS (Invitrogen) and 1% 
penicillin/streptomycin (Invitrogen). Lymphocytes were then stimulated by adding 
phytohemagglutinin (PHA-P, Sigma Chemical Co., St. Louis, MO) and incubated at 
37°C/5% CO2. Forty-four hours after PHA stimulation cyt-B (Sigma Chemical Co.) was 
added to block cytokinesis. Twenty-eight hours after cyt-B addition, cells were 
harvested by centrifugation, hypotonically treated with 0.075M 4°C KCl, and fixed with 
methanol:acetic acid (24:1 ratio) for 30 min at room temperature. Lymphocytes, in fresh 
fixative, were dropped into clean, iced slides, air-dried and stained with 10% Giemsa for 
5–10 min at pH 7 (20). 
MN count was performed on an average of 2000 binucleated lymphocytes (1000 
binucleated cells per slide) with preserved cytoplasms (duplicate cultures per sample) 
following the criteria established by the HUMN for MN and apoptotic cells (21). The 
MN assay was performed blind with respect to maternal smoking status. 
 
 
Testing the MN assay with BPDE 
 
Over 4 wk, the lymphocytes from the cord blood from a further four healthy, 
nonsmoking mothers were also isolated as described above. These women were not 
included in the control nonsmoking control group and their samples were only used for 
the purposes of validation of the assay. 
 
After 39 h of culture, a range of concentrations of BPDE (with THF as co-solvent) 
(Midwest Research Institute, Kansas City, MO) was added for a period of 5 h. Cells 
were then washed with PBS to remove nonincorporated BPDE, cyt-B was added, and 
the protocol was continued as described above. 
 
 
Statistical analysis  
 
In the design of the internal validation of the MN assay, one-way ANOVA was used to 
test if the mean number of MN increased with BPDE dose. The Dunnett multiple 
contrast test was used to evaluate differences among pairs of MN means at different 
BPDE doses. The nonparametric Kruskal-Wallis test was used to test whether the 
number of apoptotic cells varied with BPDE dose and the Mann-Whitney a posteriori 
test was used to evaluate differences among means of apoptotic cells at different BPDE 
doses. 
 
Also, the nonparametric Kruskal-Wallis test was used to evaluate differences in the 
median number of MN in the smoking and nonsmoking groups. For descriptive 
purposes, the parametric variables are expressed as mean (SD) whereas the 
nonparametric are expressed as median (interquartile range). 
  
In all cases, p values were considered significant at p < 0.05 and the statistical analyses 
were carried out with SPSS version 11.0 (SPSS, Chicago, IL). 
 
 
 
RESULTS 
 
The MN assay is a delicate technique that requires manipulation of cultured cells 
submitted to a lengthy protocol (4 d). Our approach was to set-up the standard protocol 
described by the HUMN project and then modify it for application to cord blood cells. 
 
The cyt-B concentration range recommended in the literature is 3–6 µg/mL. These 
concentrations either yielded very few binucleated cells (3 µg/mL) or induced a 
cytotoxic effect on viability (6 µg/mL) so that we settled for a cyt-B concentration of 
4.5 µg/mL, which was optimal for culture conditions and yielded 35–60% of 
binucleated cells in 500 viable cells (22) (Fig. 1). 
For the final fixative stage, methanol:acetic acid in the ratio of 24:1 was used, which 
yielded an optimal staining of cells and nuclei while preserving nuclear and cytoplasm 
membrane integrity. Other ratios such as 23:2 were tried, but these resulted in paler 
cytoplasmic staining, which complicated MN scoring. 
 
An internal validation of the MN assay was then designed with the intention of 
determining the minimal dose of BPDE that significantly increases the MN index. We 
initially tried BPDE in concentrations 4, 2, 1, and 0.4 µM as indicated by the available 
literature (23,24). These concentrations turned out to be cytotoxic for cultured 
lymphocytes. We then proceeded with BPDE concentrations increasing from 3.125 nM 
to 0.2 µM (Table 1). MN and apoptotic cells were scored at seven different BPDE 
concentrations (doses 1–7), without BPDE (dose 0), and with THF alone. The test was 
done four times over 4 consecutive weeks. 
 
The mean number of MN increased with BPDE dose in a statistically significant manner 
(p < 0.0001, ANOVA) and the Dunnett a posteriori test showed that the minimal 
detectable effect was induced by dose 3, which corresponded to 12.5 nM BPDE (p = 
0.003). No significant differences in the MN scores were detected at doses higher than 
12.5 nM or between the THF control and doses from 0 to 6.25 nM BPDE (Fig. 2). 
 
The number of apoptotic cells also statistically increased with BPDE dose (p = 0.001, 
Kruskal-Wallis test) and the Mann-Whitney a posteriori test showed that the minimal 
detectable effect was induced, again, by 12.5 nM BPDE (p = 0.029) (Fig. 2). 
  
We detected no effect of THF on MN index or apoptotic cell score, so that the BPDE 
co-solvent was not per se cytotoxic for our lymphocyte cultures. 
 
After validation, the adapted MN assay was used to determine the number of MN in 
cord blood samples from 102 nonsmoking mothers and 41 who smoked 10 or more 
cigarettes per day during pregnancy. The median (IQR) number of MN in cord blood 
samples from the mothers who smoked was 4 (1; 10.5), which was significantly higher 
than that of samples coming from nonsmoking pregnant women, 3 (0; 8) (Kruskal-
Wallis, p = 0.016; Fig. 3). 
 
For all cases in which mother and father gave partially contradictory answers in their 
questionnaires (n = 10), the cotinine levels in maternal urine were determined by gas 
chromatography–mass spectrometry, whose sensitivity is reported to be 20 ng/mL. Six 
out of the 10 samples tested came from nonsmoking mothers and their median cotinine 
concentration was 20.5 ng/mL (20; 26). The remaining four cases were classified, on the 
basis of their cotinine determinations, 500 ng/mL (206; 717), as belonging to the 
smoking group. 
 
 
 
DISCUSSION 
 
Tobacco consumption among women is increasing and has negative effects on fertility 
and gestation (3). It is estimated that between 12 and 20% of women smoke during 
pregnancy (4), but the exact percentage is difficult to establish because many pregnant 
smokers deny smoking when asked by their doctor. Indeed, one of the difficulties of this 
study was to find pregnant women who were still smoking 10 or more cigarettes per 
day. 
 
Although there are various studies which have found genetic instability (indicated by 
the presence of chromosomal aberrations, sister chromatid exchanges and/or an 
increased number of MN) in the peripheral blood cells of smokers (reviewed in 25,26), 
the effects of tobacco-specific metabolites on the fetus are poorly documented. It is 
known that some compounds in tobacco smoke can cross the placental barrier and the 
presence of tobacco-specific metabolites has been detected in the fetal fluids and the 
urine of fetuses and newborns (6,7). Furthermore, such compounds have been shown to 
induce alterations in fetal growth and development (5). 
 
Likewise, studies that evaluate whether the frequency of MN increases in individuals 
who smoke are controversial, and both negative (11–13) and positive (14–16) 
correlations have been detected. 
 
To our knowledge, there is only one study that specifically analyzes the frequency of 
MN in children (2–15 y) exposed to environmental tobacco smoke (ETS), and this study 
concluded that ETS-exposed children showed significantly higher MN frequencies than 
non-ETS-exposed children (27). In a recent meta-analysis and review of the literature, 
Neri and co-workers (28) reported that chromosome aberrations and MN were 
consistently increased in children exposed to environmental pollutants. They also 
conclude that in utero exposure to tobacco smoke compounds were associated with 
increased frequencies of DNA and Hb adducts and chromosomal aberrations. Their 
conclusions, as those reported herein, argue for a susceptibility of the fetus to tobacco 
smoke. 
 
In a recent study, de la Chica and co-workers (8) detected a significant increase in the 
number of chromosomal gaps, breaks, and structural aberrations in amniocytes from 
women who smoked 10 or more cigarettes per day during pregnancy. The data reported 
here indicate increased MN in cord blood cells from such mothers (p = 0.016). Our 
results corroborate those of de la Chica and co-workers and support the hypothesis that 
tobacco compounds are able to induce chromosomal losses and/or breaks. 
 
One of the main limitations in the published studies that aim to correlate the damage 
induced by tobacco smoke with chromatid-type chromosomal aberrations is that such 
aberrations are usually formed in the last round of replication before metaphase scoring 
and, therefore, they are formed in culture and not in the exposed individual. The MN 
assay detects both the chromatid and chromosome-type chromosomal aberrations and 
cell division is a necessary condition for MN appearance because only the acentric 
fragments excluded from daughter cell nuclei at telophase can produce MN (29). In 
some studies, the lack of correlation between results in terms of the frequencies of 
chromosomal aberrations and/or sister chromatid exchanges and MN (11) may be due to 
the fact that aberration frequencies are determined at a single point in time and are 
considered instantaneous mean frequencies, whereas those of MN are running means 
based on the cumulative number of MN derived from all divisions before the time of 
scoring (30). 
 
Age is a host factor that may be involved in determining the baseline number of MN 
(9,10). To rule out a possible effect of age on the number of MN detected, while we 
selected samples from a randomly chosen consecutive series of mothers, we excluded 
mothers at the age extremes, so that the smoking and nonsmoking groups did not differ 
in maternal age (p = 0.547, data not shown). In the report by de la Chica et al. (8), the 
mean age of the smoking group was significantly higher than that of the nonsmoking 
group. Nevertheless, the authors found that the increase in chromosomal aberrations 
was statistically significant whether maternal age was included as a covariate or not. 
 
In our study, the overall average MN frequency was 3.5 (data not shown) which is in 
good agreement with previous studies that analyze the frequency of MN in healthy 
children (11). It is also interesting to observe that the mean MN frequency was not 
significantly different for male and female newborns (p = 0.909) and neither was it 
significantly different for mothers over 35 y old at time of giving birth (p = 0.203). In a 
recent review of the MN frequency in children exposed to environmental mutagens, it 
was concluded that the consistency of the results from the different studies argues 
against any clear effect of gender on MN frequency (31,32). 
 
The MN assay is an alternative to the conventional test for chromosomal aberrations, 
which analyzes the alterations present in metaphase preparations. In this sense, the MN 
assay is useful to detect both structural (clastogenic effect) and numerical chromosomal 
aberrations (aneugenic effect). Other advantages of the technique are its sensitivity 
(given that MN are scored in cells that have completed a nuclear division), increased 
power of statistical testing when scoring thousands instead of hundreds of cells, and the 
reduced costs of the assay (33). Our results, although preliminary, support the 
hypothesis that smoking during pregnancy increases the genetic instability of the fetus, 
and that the MN assay is a valid tool to detect such an instability. 
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Figure 1. Cord blood lymphocyte preparations of the MN assay at 40x: (a) 3 µ/mL, (b) 
4.5 µg/mL, and (c) 6 µg/mL of cytochalasin-B, respectively. 
 
 
 
 
 
 
 
 
 
Figure 2. (A) Schematic representation of the MN index and number of apoptotic cells 
in the different BPDE doses tested. As indicated by the different fill color, the minimal 
detectable effect was induced by 12.5 nM BPDE, both for MN (p = 0.003) and for 
apoptotic cells (p = 0.029). (B) Microscope view of BN cells with MN (1–3) and cells in 
different stages of apoptosis (4–6). 
 
  
 
 
Figure 3. Comparison of the MN frequency in fetal blood samples from smoking (n = 
41) and nonsmoking mothers (n = 102). The values are expressed as median and 
interquartile range, and outliers are marked as circles. The median number of MN in 
cord blood samples from the mothers who smoked was 4 (1; 10.5), which was 
significantly higher than that of nonsmoking pregnant women, 3 (0; 8) (Kruskal-Wallis, 
p = 0.016). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Summary of MN scores and apoptotic indexes during                
the internal validation protocol 
BPDE dose 
MN/1000 
binucleated cells 
Mean (SD) 
Apoptotic cells/1000 
viable cells 
Median* (IQR) 
Negative (THF) 5 (1.22) 60.5 (51.5; 68.75) 
Dose 0 4 (0.71) 61.5 (40.5; 70.5) 
Dose 1 (3.125 nM) 7.5 (1.66) 89 (73.5; 95.5) 
Dose 2 (6.25 nM) 8.75 (1.48) 108.5 (72.5; 175.25) 
Dose 3 (12.5 nM) 13.5 (2.69)† 141.5 (76.25; 206.75)‡ 
Dose 4 (25 nM) 15.5 (2.69) 173 (88.25; 257) 
Dose 5 (50 nM) 15 (3.00) 235 (178.75; 294.25) 
Dose 6 (0.1 µM) 16 (2.92) 304 (290.5; 310) 
Dose 7 (0.2 µM) 17.25 (4.21) 413 (385; 495) 
The mean number of MN increased with BPDE dose and the minimal 
detectable effect was induced by 12.5 nM BPDE (p < 0.0001, ANOVA; p = 
0.003; Dunnett a posteriori test). The number of apoptotic cells also 
statistically increased with BPDE dose, and the minimal detectable effect was 
induced by 12.5 nM BPDE (p = 0.001, Kruskal-Wallis test; ( p = 0.029, Mann-
Whitney a posteriori test). 
* IQR, Interquartile range. 
 
 
 
 
 
